Dear Reader,
Biotech Frontiers was slated to launch later this year…
But we couldn’t wait any longer…
About 25% of the biotech sector is now trading below cash value.
These stocks are low-hanging fruit for investors, and we will likely never see anything so tempting again.
As analyst Erez Kalir revealed in our interview, hundreds of high-quality biotech firms have been suppressed to prices 10, 20, even 30 times lower than any fair valuation.
These companies haven’t just been beaten down…
They’ve been indiscriminately, and unfairly depressed.
However, with the Federal Reserve now signaling that it’s done raising interest rates – and could soon start cutting them – Erez believes we could see an imminent, and historic, biotech boom.
…a rapid and sharp uptick in prices that could impact these stocks significantly.
In fact, it’s already happening.
Since our interview, eight of the first 10 companies Erez has identified for members of Biotech Frontiers have started to rally – already surging by a combined 190% in less than a month.
But this could be just the beginning…
We believe these 10 companies have far more room to grow as all but one of them is still trading below cash value.
And this is just a taste of what’s to come.
As Erez explained, there are hundreds of incredible biotech companies out there that are trading for a fraction of their value.
On top of that…
The intersection of AI and drug discovery is also going to revolutionize medicine and help drug developers create new treatments at a faster rate, and far more frequently.
This is why Erez has decided to join Porter & Co.
Not only do investors have the opportunity to capitalize on what is arguably the biggest pricing discrepancy in stock market history…
But with the emergence of AI, we are also going to see a rapid increase in the number of new drugs being developed.
As one of the few people who not only understands medicine but also the regulatory process that’s involved in approving new drugs…
Erez is the one person I know who can consistently and reliably find biotech opportunities that have explosive upside potential.
He has a long and proven history of doing just that, not only for his hedge fund clients but for a notable billionaire.
Biotech Frontiers is the first venture where Erez will be communicating directly with you.
Every month, Erez will provide details on the most exciting developments in modern medicine and the specific investment opportunities that go along with those developments.
He will share his own proprietary techniques and strategies for navigating the sector.
He will conduct exclusive interviews with some of the most reputable biologists, chemists and engineers in the field.
And he will be exposing a side of the industry few people get to see.
I’ll go so far as to say: I believe Biotech Frontiers has the potential to be one of the greatest performing financial research advisories of all time.
That’s a big claim, I know.
But as we showed you today, the environment for biotech investing has arguably never been more lucrative and there is nobody I’d rather have navigating the market for me than Erez Kalir.
He’s a former hedge fund co-founder, money manager, and is one of the most well-connected, well-informed and well-sought after individuals in the industry.
His unique background in law, medicine, and finance has allowed him to generate some exceptional returns in biotech, including: 1,300% on Soleno Therapeutics, 400% on BiondVax, 400% on Idorsia and more…
Now, as the editor of Biotech Frontiers, he is going to help you navigate the world of biotech investing with a depth of knowledge, experience, and connections that are unsurpassed by any other analyst.
In his new report, The Big Biotech Rebound, you’ll get details on the 10 companies Erez believes have the greatest potential in the months and years ahead.
But these companies are just a sneak peek of what’s to come.
However, because investing in biotech is not for everyone, I’m only making Biotech Frontiers available to my most serious and experienced readers – my Partner Pass members.
